medigraphic.com

2018, Number 3

<< Back Next >>

Rev Hematol Mex 2018; 19 (3)

Irregular erythrocyte antibodies detected at State Center of Blood Transfusion of Chihuahua State, Mexico

Terrazas-Rascón JA, Rivera-Abaid MM, Carrera-Hernández MM, Santana-Rodríguez VM, Moreno-Brito V, Leal-Berumen I, Duque-Rodríguez J, Licón-Trillo Á

Language: Spanish
References: 14
Page: 109-114
PDF size: 196.74 Kb.


ABSTRACT

Background: The State Center of Blood Transfusion (CETS) of the state of Chihuahua is responsible for the donation and altruistic distribution of blood and derivatives in Chihuahua, as well as the detection of probable donors with transmissible infectious processes, and occasionally the meeting of antibodies irregular erythrocytes prior to a blood transfusion.
Objective: To describe la presence of irregular erythrocyte antibodies and the related diseases.
Material and Method: An observational, descriptive and retrospective study carried out in the CETS of Chihuahua that describes the frequency of irregular erythrocyte antibodies detected from 2010 to 2015, relating them to blood type, gender, age and clinical factors.
Results: A total of 152 records with a positive result of irregular antibodies were located out of a total of 45,878 studies conducted in the mentioned period. The data analyzed show that the female sex had a prevalence of alloantibodies of 78.2% compared to men (p ‹ 0.0001); 70.5% of people were over 30 years old; 35.1% of the patients had a positive transfusion history. Irregular anti-D antibody appeared in 21.7% of cases, being the most frequent in females (p ‹ 0.002). The most probable genotype R1r was the most prevalent in our population.
Conclusions: Knowledge of the association between the clinical conditions of patients and alloimmunization will lead to a better understanding and management of transfusion medicine.


REFERENCES

  1. Fatalities reported to FDA following blood collection and transfusion. Annual summary for fiscal year 2013. Actualizado el 10 de junio de 2015. Revisado el 20 de septiembre de 2017. Disponible en: http://www.fda.gov/BiologicsBloodVaccines/ SafetyAvailability/ReportaProblem/Transfusion- DonationFatalities/ucm391574.htm.

  2. Storry JR, Castilho L, Daniels G, Flegel WA, Garratty G, de Haas M, et al. International Society of Blood Transfusion Working Party on red cell immunogenetics and blood group terminology: Cancun report (2012). Vox Sang. 2014;107:90-6.

  3. Barbolla L. Manual Práctico de Medicina Transfusional. 1ª ed. España, editorial Acción Médica. 2002;71-74.

  4. Dean L. Blood groups and red cell antigens. United States of America, National Center for Biotechnology Information (NCBI), 2005;1-5.

  5. Martins PRJ, Alves VM, Pereira GA, Moraes-Souza H. Frequency of irregular antibodies in multipletransfused patients at the Regional Blood Bank of Uberaba, from 1997 to 2005. Rev Bras Hematol Hemoter 2008;30(4):272-276.

  6. Hoeltge GA, Domen RE, Rybicki LA, Schaffer PA. Multiple red cell transfusions and alloimmunization. Experience with 6996 antibodies detected in a total of 159,262 patients from 1985 to 1993. Arch Pathol Lab Med 1995;119(1):42- 45.

  7. Zalpuri S, Zwaginga JJ, le Cessie S, Elshuis J, Schonewille H, van der Bom JG. Red-blood-cell alloimmunization and number of red-blood-cell transfusions. Vox Sang 2012;102(2):144-149.

  8. Bauer MP, Wiersum-Osselton J, Schipperus M, Vandenbroucke JP, Briët E. Clinical predictors of alloimmunization after red blood cell transfusion. Transfusion 2007;47:2066- 2071.

  9. Brecher ME. Technical Manual. 15th ed. USA: American Association of Blood Banks, 2005;423-453.

  10. Rodríguez-Moyado R. El Banco de Sangre y la Medicina Transfusional, 2ª ed. México: Editorial Médica Panamericana, 2004;45-85.

  11. Santos FW, Magalhães SM, Mota RM, Pitombeira MH. Post transfusion red alloimmunization in patients with acute disorders and medical emergencies. Rev Bras Hematol Hemoter 2007;29(4):369-372.

  12. Alcaraz-López JL. III. La prueba cruzada incompatible y su correlación clínica. Gac Méd Méx 2003;139(Suppl 3):S25-S27.

  13. Ki-Ho K, Byung-Hoon Y, Kye-Min K, Woo-Yong L, et al. Frequency of unexpected antibody and consideration during transfusion. Korean J Anesthesiol 2012;62(5):412-417.

  14. Dueñas RVH, Cortés BA, Rovetto P, Neuta APA. Embarazo y transfusión y su asociación con aloanticuerpos inesperados de significancia clínica contra antígenos eritrocitarios. Colombia Med 1999;30:26-31.




2020     |     www.medigraphic.com